Literature DB >> 22205196

Pharmacokinetic similarity of biologics: analysis using nonlinear mixed-effects modeling.

A Dubois1, S Gsteiger, S Balser, E Pigeolet, J L Steimer, G Pillai, F Mentré.   

Abstract

Our objective was to show, using two examples, that a pharmacokinetic (PK) similarity analysis can be performed using nonlinear mixed-effects models (NLMEM). We used two studies that compared different biosimilars: a three-way crossover trial with somatropin and a parallel-group trial with epoetin-α. For both data sets, the results of NLMEM-based analysis were compared with those of noncompartmental analysis (NCA). For the latter analysis, we performed an NLMEM-based equivalence Wald test on secondary parameters of the model: the area under the curve and the maximal concentration. Somatropin PK was described by a one-compartment model and epoetin-α PK by a two-compartment model with linear and Michaelis-Menten elimination. For both studies, similarity of PK was demonstrated by means of both NCA and NLMEM, and both methods led to similar results. Therefore, for establishing similarity, PK data can be analyzed by either of the methods. NCA is an easier approach because it does not require data modeling; however, NLMEM leads to a better understanding of the underlying biological system.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22205196      PMCID: PMC3400548          DOI: 10.1038/clpt.2011.216

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  31 in total

1.  Estimation of rhG-CSF absorption kinetics after subcutaneous administration using a modified Wagner-Nelson method with a nonlinear elimination model.

Authors:  N Hayashi; H Aso; M Higashida; H Kinoshita; S Ohdo; E Yukawa; S Higuchi
Journal:  Eur J Pharm Sci       Date:  2001-05       Impact factor: 4.384

2.  Characterization of the highly variable bioavailability of tiludronate in normal volunteers using population pharmacokinetic methodologies.

Authors:  G A Maier; G F Lockwood; J A Oppermann; G Wei; P Bauer; J Fedler-Kelly; T Grasela
Journal:  Eur J Drug Metab Pharmacokinet       Date:  1999 Jul-Sep       Impact factor: 2.441

3.  Ways to fit a PK model with some data below the quantification limit.

Authors:  S L Beal
Journal:  J Pharmacokinet Pharmacodyn       Date:  2001-10       Impact factor: 2.745

4.  Statisticians and pharmacokineticists: what they can still learn from each other.

Authors:  S Senn
Journal:  Clin Pharmacol Ther       Date:  2010-07-07       Impact factor: 6.875

5.  Bioequivalence between novel ready-to-use liquid formulations of the recombinant human GH Omnitrope and the original lyophilized formulations for reconstitution of Omnitrope and Genotropin.

Authors:  Uwe Fuhr; Daniel Tuculanu; Alexander Berghout; Sigrid Balser; Arnd Schwebig; Paul Saenger
Journal:  Eur J Endocrinol       Date:  2010-03-23       Impact factor: 6.664

6.  Design evaluation and optimisation in multiple response nonlinear mixed effect models: PFIM 3.0.

Authors:  Caroline Bazzoli; Sylvie Retout; France Mentré
Journal:  Comput Methods Programs Biomed       Date:  2009-11-04       Impact factor: 5.428

7.  Bioequivalence tests based on individual estimates using non-compartmental or model-based analyses: evaluation of estimates of sample means and type I error for different designs.

Authors:  Anne Dubois; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Pharm Res       Date:  2009-10-30       Impact factor: 4.200

8.  Bioequivalence studies of omnitrope, the first biosimilar/rhGH follow-on protein: two comparative phase 1 randomized studies and population pharmacokinetic analysis.

Authors:  Richard Stanhope; Fritz Sörgel; Patricia Gravel; Yannic B Pannatier Schuetz; Markus Zabransky; Michael Muenzberg
Journal:  J Clin Pharmacol       Date:  2010-02-19       Impact factor: 3.126

9.  Model-based analyses of bioequivalence crossover trials using the stochastic approximation expectation maximisation algorithm.

Authors:  Anne Dubois; Marc Lavielle; Sandro Gsteiger; Etienne Pigeolet; France Mentré
Journal:  Stat Med       Date:  2011-07-26       Impact factor: 2.373

10.  Selection between Michaelis-Menten and target-mediated drug disposition pharmacokinetic models.

Authors:  Xiaoyu Yan; Donald E Mager; Wojciech Krzyzanski
Journal:  J Pharmacokinet Pharmacodyn       Date:  2009-12-10       Impact factor: 2.745

View more
  7 in total

1.  Population Pharmacokinetic Analysis of the Oral Absorption Process and Explaining Intra-Subject Variability in Plasma Exposures of Imatinib in Healthy Volunteers.

Authors:  Ali-Akbar Golabchifar; Saeed Rezaee; Nahid Mobarghei Dinan; Abbas Kebriaeezadeh; Mohammad-Reza Rouini
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2016-10       Impact factor: 2.441

2.  Application of Pharmacometric Analysis in the Design of Clinical Pharmacology Studies for Biosimilar Development.

Authors:  Peijuan Zhu; Sherwin K B Sy; Andrej Skerjanec
Journal:  AAPS J       Date:  2018-03-07       Impact factor: 4.009

3.  Population pharmacokinetics of adalimumab biosimilar adalimumab-adbm and reference product in healthy subjects and patients with rheumatoid arthritis to assess pharmacokinetic similarity.

Authors:  Jia Kang; Rena J Eudy-Byrne; John Mondick; William Knebel; Girish Jayadeva; Karl-Heinz Liesenfeld
Journal:  Br J Clin Pharmacol       Date:  2020-06-11       Impact factor: 4.335

Review 4.  Allometric scaling of therapeutic monoclonal antibodies in preclinical and clinical settings.

Authors:  Eva Germovsek; Ming Cheng; Craig Giragossian
Journal:  MAbs       Date:  2021 Jan-Dec       Impact factor: 5.857

5.  Impact of model misspecification on model-based tests in PK studies with parallel design: real case and simulation studies.

Authors:  Mélanie Guhl; François Mercier; Carsten Hofmann; Satish Sharan; Mark Donnelly; Kairui Feng; Wanjie Sun; Guoying Sun; Stella Grosser; Liang Zhao; Lanyan Fang; France Mentré; Emmanuelle Comets; Julie Bertrand
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-09-16       Impact factor: 2.410

6.  Use of population approach non-linear mixed effects models in the evaluation of biosimilarity of monoclonal antibodies.

Authors:  Joannes A A Reijers; T van Donge; F M L Schepers; J Burggraaf; J Stevens
Journal:  Eur J Clin Pharmacol       Date:  2016-08-11       Impact factor: 2.953

Review 7.  Performing and interpreting individual pharmacokinetic profiles in patients with Hemophilia A or B: Rationale and general considerations.

Authors:  Alfonso Iorio; Andrea N Edginton; Victor Blanchette; Jan Blatny; Ana Boban; Marjon Cnossen; Peter Collins; Stacy E Croteau; Katheljin Fischer; Daniel P Hart; Shinya Ito; Joan Korth-Bradley; Stefan Lethagen; David Lillicrap; Mike Makris; Ron Mathôt; Massimo Morfini; Ellis J Neufeld; Jeffrey Spears
Journal:  Res Pract Thromb Haemost       Date:  2018-05-20
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.